天眼查商业履历信息显示，北京昭衍新药研究中心股份有限公司，成立于1998年，位于北京市，是一家 以从事研究和试验发展为主的企业。企业注册资本53564.4275万人民币，实缴资本4560.33万人民币。公 司法定代表人为冯宇霞。 通过天眼查大数据分析，北京昭衍新药研究中心股份有限公司共对外投资了20家企业，参与招投标项目 44次，知识产权方面有商标信息70条，专利信息54条，此外企业还拥有行政许可44个。 来源：金融界 金融界消息 截至2025年8月15日收盘，昭衍新药（603127）报收于32.96元，上涨2.33%，换手率 4.43%，成交量27.90万手，成交金额9.13亿元。 资金流向方面，今日主力资金净流出1112.03万元，占比成交额1.22%。其中，超大单净流出433.45万 元、占成交额0.47%，大单净流出678.58万元、占成交额0.74%，中单净流出流入967.36万元、占成交额 1.06%，小单净流入144.67万元、占成交额0.16%。 昭衍新药最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少11.54%，归属净利 润4111.95万元，同比增长115.11 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 董事會召開日期 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2025年8月26日（星 期 二）舉 行 董 事 會 會 議，以 考慮及通過本集團截至2025年6月30日 止 的 六 個 月 中 期 業 績，以 及 處 理 其 他 事 項。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 馮宇霞 中 國，北 京 2025年8月14日 於 本 公 告 日 期，本 公 司 董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 ...

格隆汇8月14日丨昭衍新药(06127.HK)公布，公司将于2025年8月26日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

资料显示，北京昭衍新药研究中心股份有限公司(股票代码:603127.SH/6127.HK),成立于1995年,是专业化 的药物研发服务外包企业(CRO),总部位于北京,在北京、苏州、重庆、广州、无锡、梧州、南宁、云 南、上海、美国加州及波士顿设有子公司,昭衍新药建立有符合国际规范的质量管理体系(CNAS/ILAC- MRA认证),具备中国NMPA、美国FDA、日本PMDA、韩国MFDS及经合组织OECD的GLP资质以及国际 AAALAC(动物福利)认证资质,评价资料满足全球药品注册要求。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 8月14日，上证指数跌0.46%，收报3666.44点，恒生指数跌0.37%，收报25519.32点。 XD昭衍新AH溢价达43.47%，位居AH股溢价率第79位。当日收盘，XD昭衍新A股报32.21元，跌幅 5.74%，H股报24.56港元，下跌1.52%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 主 席 馮宇霞 中 國，北 京 2025年8月14日 （股 份 代 號：6127） 董事會召開日期 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2025年8月26日（星 期 二）舉 行 董 事 會 會 議，以 考慮及通過本集團截至2025年6月30日 止 的 六 個 月 中 期 業 績，以 及 處 理 其 他 事 項。 承董事會命 北京昭衍新藥研究中心股份有限公司 於 本 公 告 日 期，本 公 司 董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 ...

Market Overview - On August 14, the medical services sector declined by 0.47%, with XD Zhaoyan leading the drop [1] - The Shanghai Composite Index closed at 3666.44, down 0.46%, while the Shenzhen Component Index closed at 11451.43, down 0.87% [1] Top Gainers in Medical Services - Nanjing Momo Biological Technology (688265) saw a closing price of 60.60, up 16.20% with a trading volume of 45,800 shares and a transaction value of 262 million [1] - Innovation Medical (002173) closed at 24.92, up 10.02% with a trading volume of 1,071,000 shares and a transaction value of 2.609 billion [1] - Sanbo Brain Science (301293) closed at 67.82, up 8.51% with a trading volume of 396,800 shares and a transaction value of 2.618 billion [1] Top Losers in Medical Services - XD Zhaoyan (603127) closed at 32.21, down 5.74% with a trading volume of 455,800 shares and a transaction value of 1.497 billion [2] - Chengda Pharmaceutical (301201) closed at 27.34, down 5.50% with a trading volume of 98,100 shares and a transaction value of 276 million [2] - ST Biological (000504) closed at 10.75, down 5.04% with a trading volume of 110,000 shares and a transaction value of 120 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 364 million from institutional investors, while retail investors saw a net inflow of 138 million [2] - Notable net inflows from retail investors were observed in Innovation Medical (002173) with 117 million, while significant outflows were noted in Sanbo Brain Science (301293) with 46 million [3]

Policy Developments - Shanghai has initiated the online listing for the first batch of traditional Chinese medicine centralized procurement expansion, with the application period from August 12 to August 29, 2025 [1] Drug and Device Approvals - Hualan Vaccine has received approval for clinical trials of its lyophilized Hib conjugate vaccine, which is expected to induce immune response against Hib [2] - Insmed announced that the FDA has approved its first-in-class oral drug Brinsupri for treating non-cystic fibrosis bronchiectasis in patients aged 12 and older [3] - The National Medical Products Administration has received a market application for the intraocular injection of Bevacizumab from Fuhong Hanlin and Eddingpharm, marking the second such application in China [4] - Heng Rui Medicine has received approval for clinical trials of its innovative drug SHR-A2102 in combination with other treatments for recurrent/metastatic head and neck squamous cell carcinoma [5] Capital Market Activities - Inokang Medical Technology has started the listing guidance process with Huatai Securities, as disclosed by the China Securities Regulatory Commission [6] - Inokang was founded in 2014 by returnees and experienced professionals in the medical industry, and it has been recognized as a national high-tech enterprise [7] - Rejuve Bio announced a capital increase of 100 million yuan for its subsidiary ShunJing Biomedical Technology, with the company's stake decreasing from 45.5833% to 43.1842% [8] Industry Events - Zhifei Biological has completed the first nationwide vaccination of its quadrivalent influenza vaccine, highlighting the competitive landscape and market potential in China's influenza vaccine sector [10] - Zhonghui Bio's quadrivalent influenza vaccine has passed the preliminary review for inclusion in the national commercial health insurance innovative drug directory [11] - BeiGene anticipates that its drug Sotucumab will receive its first global approval by the end of 2026, with multiple milestone events expected soon [12] Public Sentiment Alerts - The re-registration application for Green Valley Pharmaceutical's mannitol sodium capsules has not been approved, indicating ongoing challenges for this controversial Alzheimer's drug [14] Shareholder Activities - Former Vice Chairman of Zhaoyan New Drug plans to reduce his holdings by up to 352.45 million shares due to personal financial needs, representing 0.4703% of the company's total share capital [15]

Group 1: Industry Developments - Shanghai has initiated the online listing for the first batch of traditional Chinese medicine centralized procurement expansion, with the application period from August 12 to August 29, 2025 [1] - The Shanghai Market Supervision Administration reported a significant decline in the illegal rate of medical advertisements over the past five years, dropping from 3.89% in 2020 to 1.57% in 2024, a decrease of approximately 60% [2] - The first FDA-approved treatment for non-cystic fibrosis bronchiectasis (NCFB), Brinsupri, has been announced by Insmed, marking a significant milestone in the treatment options available for this condition [3] - The National Medical Products Administration has received a market application for the intraocular injection of Bevacizumab, indicating progress in ophthalmic drug development [4] - Heng Rui Medicine has received approval for clinical trials of its innovative drug SHR-A2102 for the treatment of recurrent/metastatic head and neck squamous cell carcinoma [5] Group 2: Capital Market Activities - Inokang Medical Technology has started the listing guidance process with Huatai Securities, indicating its intention to go public [6] - Rejuvenation Bio announced a capital increase of 100 million yuan for its subsidiary, Shun Jing Biomedical Technology, with a share price set at 25 yuan per registered capital [7] - Innovation Medical holds a 40% stake in Bole Brain Machine, which focuses on core technology research and product design in the medical rehabilitation field [8] Group 3: Vaccine and Pharmaceutical Developments - Zhifei Biological has completed the first nationwide vaccination for its quadrivalent influenza vaccine, showcasing advancements in vaccine distribution [9] - Zhonghui Bio's quadrivalent influenza vaccine has passed the preliminary review for inclusion in the national commercial health insurance innovative drug directory [10] - BeiGene anticipates that its drug Sotukimab will receive its first global approval by the end of 2026, with multiple clinical trials underway [11] Group 4: Regulatory and Market Challenges - The re-registration application for Green Valley Pharmaceutical's mannitol sodium capsules has not been approved, posing challenges for this controversial Alzheimer's drug [12] - There have been reports of supply shortages and rising prices for the mannitol sodium capsules, indicating market pressures and patient access issues [13] - Zhaoyan New Drug's former vice chairman plans to reduce his holdings by up to 352,450 shares, reflecting personal financial needs [14]

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by former Vice Chairman Zuo Conglin of Beijing Zhaoyan New Drug Research Center Co., Ltd., due to personal financial needs, involving the potential sale of up to 3,524,500 shares, which represents 0.4703% of the company's total share capital [1][3]. Group 1: Shareholder Information - As of the announcement date, Zuo Conglin holds 14,098,317 shares, accounting for 1.8811% of the total share capital of the company [1]. - The shares held by Zuo Conglin originated from pre-IPO restricted shares, equity incentive shares, and shares from capital reserve conversion [1]. Group 2: Reduction Plan Details - The reduction is planned to occur between August 19, 2025, and August 29, 2025, through centralized bidding or block trading [1]. - The reduction quantity will be adjusted if there are corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period [1]. - Zuo Conglin has committed to a long-term holding intention and will not sell shares below the issuance price, with adjustments for any corporate actions affecting share price [3]. Group 3: Compliance and Regulations - The reduction plan is consistent with previously disclosed commitments, and Zuo Conglin will adhere to relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [3][4]. - There are no other arrangements or risks that could lead to a change in the company's control due to this reduction plan [2][4].

股东减持 A 股股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 股东持股的基本情况 截至本公告披露日，北京昭衍新药研究中心股份有限公司（以下简称"公司"） 原副董事长左从林（已离任）持有公司股份 14,098,317 股，占公司总股本 1.8811%。 上述股份来源于首发前限售股份、股权激励股份及公司资本公积金转增股份等。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-030 北京昭衍新药研究中心股份有限公司 ? 减持计划的主要内容 左从林因自身资金需求，计划根据市场价格情况，自本公告披露之日起 3 个 交易日后即 2025 年 8 月 19 日至 2025 年 8 月 29 日内通过集中竞价或大宗交易的 方式减持其所持有公司股份不超过 3,524,500 股，减持比例不超过公司总股本的 等股本除权事项的，减持数量将进行相应调整。 一、减持主体的基本情况 | 股东名称 | 左从林 | | | | | --- | --- | --- | --- | --- | | | ...